martes, 31 de octubre de 2023

Pembrolizumab as a first-line treatment for advanced gastric cancer

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00526-0/fulltext?dgcid=hubspot_email_conferencealerts_esmo23&utm_campaign=conferencealerts&utm_medium=email&_hsmi=278989396&_hsenc=p2ANqtz--y-lgGP-7TkTSrXc-68G5e8cUOCHqIHi0jECtglaMV-k8nQaxTxg_0DM1s00UIVPnSbKDNY28xlDJIRSVDyxScqP0oRg&utm_content=278989396&utm_source=hs_email

No hay comentarios:

Publicar un comentario